<ѻýҕl>Olympic Gold Medalist Nathan Adrian's Testicular Cancerѻýҕl> The swimmer's diagnosis, treatment, and an "extra year" of pandemic prep for Toyko Apr 20, 2021
<ѻýҕl>Poloxamer 188 Flops for Sickle Cell Disease Painѻýҕl> Study found no difference in duration of vaso-occlusive episodes versus placebo Apr 20, 2021
<ѻýҕl>New Anti-PD1 Drugs Boost Survival in Treated Lung Cancerѻýҕl> Questions about generalizability of results with China-developed therapies Apr 14, 2021
<ѻýҕl>Another Player in Advanced Bladder Cancerѻýҕl> Accelerated FDA approval of sacituzumab govitecan after chemo, immunotherapy Apr 14, 2021
<ѻýҕl>Targeted Drug Yields Durable Responses in Rare Blood Neoplasmѻýҕl> Most advanced systemic mastocytosis patients responded to KIT D816V inhibitor Apr 13, 2021
<ѻýҕl>Another FGFR Inhibitor Active in Bile Duct Cancersѻýҕl> Clinical benefit rate of 82% in patients selected for FGFR2 fusions, rearrangements Apr 13, 2021
<ѻýҕl>Dual Targeted Tx a 'Meaningful' Option in BRAF-Mutant Gliomaѻýҕl> One-third of glioblastoma patients responded to dabrafenib-trametinib Apr 12, 2021
<ѻýҕl>More Benefit With Taxane for Aggressive Metastatic Prostate Cancerѻýҕl> Higher clinical benefit rate with front-line cabazitaxel versus androgen receptor inhibitor Apr 12, 2021
<ѻýҕl>Triple-Negative Breast Cancers Not All the Sameѻýҕl> Histology tied to treatment response, outcomes Apr 12, 2021
<ѻýҕl>A Win for Nivolumab as Preoperative Therapy for Lung Cancerѻýҕl> Pathologic CR rate 12 times higher with the addition of anti-PD-1 agent to chemo Apr 11, 2021
<ѻýҕl>Immunovirotherapy Shows Promise in Pediatric High-Grade Gliomaѻýҕl> Small study showed responses in 11 of 12 patients Apr 11, 2021
<ѻýҕl>Nivolumab Alone Prevails in Resected Melanomaѻýҕl> Adding ipilimumab in adjuvant setting failed to improve relapse-free survival Apr 11, 2021
<ѻýҕl>Mixed Results for Immunotherapy in Metastatic Prostate Cancerѻýҕl> Combination trial missed response endpoint but exceeded historical results Apr 11, 2021
<ѻýҕl>Practice-Changing Results in Metastatic Uveal Melanomaѻýҕl> Bispecific T cell-engaging tebentafusp reduces survival hazard by 50% Apr 10, 2021
<ѻýҕl>Add-On PI3K Inhibitor Wins in Relapsed, Indolent NHLѻýҕl> Adding copanlisib to rituximab also doubled CR rate, with manageable toxicity Apr 10, 2021
<ѻýҕl>From VIPIT to VITT: Thrombosis and COVID Vaccinesѻýҕl> More data support link between adenovirus vector vaccines, blood clotting, and low platelets Apr 09, 2021
<ѻýҕl>Complications Common in Excision of Retained Cervix After Hysterectomyѻýҕl> Occur in almost 40% of procedures, cancer in 18% of cases Apr 09, 2021
<ѻýҕl>Ethics Consult: Stop Treatment for Costly Patient? MD/JD Weighs Inѻýҕl> You voted, now see the results and an expert's discussion Apr 09, 2021
<ѻýҕl>Can a COX-2 Inhibitor Boost Disease-free Survival in CRC?ѻýҕl> Large trial tested addition of the agent to standard FOLFOX Apr 06, 2021
<ѻýҕl>No Cancer Risk With Commonly Used Blood Pressure Medsѻýҕl> Largest analysis yet but definitive data remain elusive Apr 05, 2021
<ѻýҕl>Anti-PD-L1 Flops in Locally Advanced Head and Neck Cancerѻýҕl> No PFS benefit from adding avelumab to chemoradiation, hazard ratio favored placebo Apr 02, 2021
<ѻýҕl>A Win for Adjuvant Immunotherapy in Esophageal Cancerѻýҕl> And other highlights from the Society of Surgical Oncology's virtual 2021 meeting Mar 31, 2021
<ѻýҕl>Triage System Gets High Marks for Ovarian Cancer Debulking Surgeryѻýҕl> Key factors predicted threefold higher risk of 90-day mortality with primary surgery Mar 26, 2021
<ѻýҕl>HIPEC Combo Doubles PFS in Advanced Ovarian Cancerѻýҕl> Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study Mar 26, 2021
<ѻýҕl>Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancerѻýҕl> Ixabepilone plus bevacizumab yielded responses in a third of patients Mar 26, 2021
<ѻýҕl>Vaccines and Rare Clotting Disorders: What's the Link?ѻýҕl> Causal relation appears possible, but evidence still indicates it's extremely rare Mar 25, 2021
<ѻýҕl>Model: Give COVID-19 Vaccine to All Patients Before Surgeryѻýҕl> Prioritizing surgical patient population could avert more COVID deaths Mar 25, 2021
<ѻýҕl>Marrow Cell Stimulator to Treat Alzheimer's Disease?ѻýҕl> Unusual approach pans out in mid-stage trial Mar 24, 2021
<ѻýҕl>Op-Ed: Blood Cancer Patients Need More COVID Vax Answersѻýҕl> Patients are left wondering, "will I be protected?" Mar 24, 2021
<ѻýҕl>Safety Reassurance for Major Class of Diabetes Drugsѻýҕl> Pooled trial data show no link to breast cancer Mar 24, 2021
<ѻýҕl>Little Benefit With Adjuvant Therapy for High-Risk Endometrial Cancerѻýҕl> Chemo prevented relapse but did not improve survival, no benefit from radiotherapy Mar 23, 2021
<ѻýҕl>Androgen Receptor Inhibitor Active in Endometrial Cancerѻýҕl> SGO: Apatinib for platinum-resistant ovarian cancer, pembrolizumab for advanced vulvar cancer Mar 22, 2021
<ѻýҕl>Hormonal IUD Shows Promise in Early Endometrial Cancerѻýҕl> Regression seen in 82% of women with precancerous lesions Mar 21, 2021
<ѻýҕl>Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancerѻýҕl> Responses in 37% of patients with AVB-500, higher without prior bevacizumab Mar 21, 2021
<ѻýҕl>Op-Ed: Primary Care and Specialty Ping Pongѻýҕl> Let's put an end to bureaucratic medicine and treat the patient in front of us Mar 21, 2021
<ѻýҕl>Is MIS Viable for Interval Debulking in Ovarian Cancer?ѻýҕl> Retrospective study compared approach versus open surgery after neoadjuvant chemotherapy Mar 21, 2021
<ѻýҕl>PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancerѻýҕl> Modest improvement in PFS with rucaparib but worse outcome for reversion mutation Mar 20, 2021
<ѻýҕl>Practice-Changing Trial in Second-Line Endometrial Cancerѻýҕl> Pembrolizumab plus lenvatinib improved median OS by nearly 7 months versus chemotherapy Mar 19, 2021
<ѻýҕl>Class of Cancer Drug Linked to Aneurysms, Artery Dissectionsѻýҕl> Database analysis finds more reports than expected with antiangiogenic drugs Mar 18, 2021
<ѻýҕl>Acupuncture Tops Usual Care for Pain in Cancer Survivorsѻýҕl> Two types of acupuncture proved superior, with one better than the other Mar 18, 2021